UVA School of Medicine emeritus professor Dr. Frederick G. Hayden helped design the trial and presented the results Wednesday ...

The measure, which passed with bipartisan support and minor changes, now heads back to the House. It is just the second ...

Treatments for dry eye disease, neuroendocrine tumors, chronic spontaneous urticaria, Barth syndrome, and migraine are under review.

The FDA’s latest draft guidance on accelerated approval for new drugs, “Expedited Program for Serious Conditions—Accelerated Approval of Drugs and Biologics,” is a game-changer for biopharmaceutical ...

A new combination pill has been given the green light by the National Institute for Health and Care Excellence (Nice) to ...

Researchers at UT Southwestern Medical Center found that tenecteplase, a newer drug, is just as safe and effective as ...

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

Positive data from a pair of acute pain studies convinced the company that its drug, which works differently than existing ...

Optum Rx, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in ...

High-grade glioma, an aggressive form of pediatric and adult brain cancer, is challenging to treat given the tumor location, ...

The FDA has approved TNKase, a new, fast-acting stroke treatment that dissolves blood clots more efficiently, marking a significant advancement in stroke therapy and clot-busting technology.

Patients enroll in phase 2 oncology trials seeking access to promising new treatments, but the risk-benefit assessments and ...